| 1. |
?Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest, 2001, 108(6): 785-791.
|
| 2. |
Cai L, Wang Z, Ji A, et al. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. PLoS One, 2012, 7(5): e36785.
|
| 3. |
Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med, 2014, 46: e99.
|
| 4. |
Liani R, Halvorsen B, Sestili S, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med, 2012, 52(8): 1318-1324.
|
| 5. |
Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med, 2015, 21(1): 37-46.
|
| 6. |
Hua W, Huang HZ, Tan LT, et al. CD36 mediated fatty acid-induced podocyte apoptosis via oxidative stress. PLoS One, 2015, 10(5): e0127507.
|
| 7. |
Pepino MY, Kuda O, Samovski D, et al. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr, 2014, 34: 281-303.
|
| 8. |
Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates thein vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol, 1997, 138(3): 707-717.
|
| 9. |
Savill J, Hogg N, Ren Y, et al. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest, 1992, 90(4): 1513-1522.
|
| 10. |
Laugerette F, Passilly-Degrace P, Patris B, et al. CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J Clin Invest, 2005, 115(11): 3177-3184.
|
| 11. |
Glatz JF, Angin Y, Steinbusch LK, et al. CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Prostaglandins Leukot Essent Fatty Acids, 2013, 88(1, SI): 71-77.
|
| 12. |
García-Monzón C, Lo Iacono O, Crespo J, et al. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest, 2014, 44(1): 65-73.
|
| 13. |
Handberg A, Skjelland M, Michelsen AE, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke, 2008, 39(11): 3092-3095.
|
| 14. |
Babaahmadi Rezaei H, Doosti M, Aminian M, et al. Compare the effect of eicosapentaenoic acid and oxidized low-density lipoprotein on the expression of CD36 and peroxisome proliferator-activated receptor gamma. Iran Biomed J, 2013, 17(2): 84-92.
|
| 15. |
Han J, Hajjar DP, Zhou X, et al. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem, 2002, 277(26): 23582-23586.
|
| 16. |
Sfeir Z, Ibrahimi A, Amri E, et al. Regulation ofFAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot Essent Fatty Acids, 1997, 57(1): 17-21.
|
| 17. |
Jiang Y, Wang M, Huang K, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun, 2012, 425(2): 121-126.
|
| 18. |
Kuchibhotla S, Vanegas D, Kennedy DJ, et al. Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A Ⅰ/Ⅱ. Cardiovasc Res, 2008, 78(1): 185-196.
|
| 19. |
Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol, 2004, 24(12): 2333-2338.
|
| 20. |
Glatz JF. Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent Fatty Acids, 2015, 93(SI): 45-49.
|
| 21. |
Wang Y, Zhou XO, Zhang Y, et al. Association of theCD36 gene with impaired glucose tolerance, impaired fasting glucose, type-2 diabetes, and lipid metabolism in essential hypertensive patients. Genet Mol Res, 2012, 11(3): 2163-2170.
|
| 22. |
Gautam S, Banerjee M. The macrophage Ox-LDL receptor, CD36 and its association with type Ⅱ diabetes mellitus. Mol Genet Metab, 2011, 102(4): 389-398.
|
| 23. |
Huen SC, Moeckel GW, Cantley LG. Macrophage-specific deletion of transforming growth factor-β1 does not prevent renal fibrosis after severe ischemia-reperfusion or obstructive injury. Am J Physiol Renal Physiol, 2013, 305(4): F477-F484.
|
| 24. |
Okamura DM, Pennathur S, Pasichnyk K, et al. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol, 2009, 20(3): 495-505.
|
| 25. |
Pennathur S, Pasichnyk K, Bahrami NM, et al. The macrophage phagocytic receptor CD36 promotes fibrogenic pathways on removal of apoptotic cells during chronic kidney injury. Am J Pathol, 2015, 185(8): 2232-2245.
|
| 26. |
Lu H, Yao K, Huang D, et al. High glucose induces upregulation of scavenger receptors and promotes maturation of dendritic cells. Cardiovasc Diabetol, 2013, 12: 80.
|
| 27. |
Hou Y, Wu M, Wei J, et al. CD36 is involved in high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Biochem Biophys Res Commun, 2015, 468(1/2): 281-286.
|
| 28. |
Souza AC, Bocharov AV, Baranova IN, et al. Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice Independent of blood pressure regulation. Kidney Int, 2016, 89(4): 809-822.
|
| 29. |
Handberg A, Norberg M, Stenlund H, et al. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. Clin Endocrinol Metab, 2010, 95(4): 1939-1946.
|
| 30. |
Kn?sgaard L, Thomsen SB, St?ckel M, et al. Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals. Nutr Diabetes, 2014, 4: e114.
|
| 31. |
Shiju TM, Mohan V, Balasubramanyam M, et al. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complications, 2015, 29(3): 400-406.
|
